Oncotelic Therapeutics, Inc. 8-K Filing

FAQ

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 8KB
• ex99-1_001.jpg (GRAPHIC) — 891KB
• ex99-1_002.jpg (GRAPHIC) — 707KB
• ex99-1_003.jpg (GRAPHIC) — 305KB
• ex99-1_004.jpg (GRAPHIC) — 325KB
• ex99-1_005.jpg (GRAPHIC) — 300KB
• ex99-1_006.jpg (GRAPHIC) — 244KB
• 0001493152-25-028921.txt ( ) — 4025KB
• otlc-20251222.xsd (EX-101.SCH) — 3KB
• otlc-20251222_lab.xml (EX-101.LAB) — 33KB
• otlc-20251222_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2025 ONCOTELIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-21990 13-3679168 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 29397 Agoura Road , Suite 107 Agoura Hills , CA 91301 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code ( 650 ) 635-7000 Not applicable. (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of class Trading Symbols Name of each exchange on which registered N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On December 22, 2025, Oncotelic Therapeutics, Inc. (the "Company") issued a press release to announce open access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data. The Company is also providing researchers access to a TGF- literature corpus comprising all known publications for TGF-- more than 125,000 PubMed abstracts- through a dedicated Discord research channel. A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Forward-Looking The Corporate Presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this communication, the words "will," "may," "would," "approximate," "expect," "intend," and similar expressions and their variants, as they relate to the Company, identify forward-looking statements. Forward looking statements contained in the Corporate Presentation include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration materially from those contained in any forward-looking statement as a result of various factors, including the risk factors included in the Company's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Disclaimer. The information in Section 8.01 of this Current Report on Form 8-K, including the

View Full Filing

View this 8-K filing on SEC EDGAR